Efor Testi Anormal Saptanan Hastalar ile Klinik, Ekokardiyografik, Biyokimyasal ve Hematolojik Parametrelerin ilişkisi

Abstract

Amaç: Anormal egzersiz stres testi olan hastalar ile normal egzersiz stres testi olan hastaların klinik, ekokardiyografik ve biyokimyasal parametrelerini karşılaştırmak Yöntem: Çalışmaya koroner arter hastalığından şüphelenilen 65 hasta dahil edildi. Tüm hastalara transtorasik ekokardiyografi uygulandı. Biyokimyasal ve hematolojik parametreler çalışıldı. Tüm hastaların Framingham, PROCAM, SCORE ve TKD risk skorları hesaplandı ve Bruce protokolüne göre egzersiz stres testi uygulandı. Hastalar normal ve anormal efor testi olmak üzere iki gruba ayrıldı. İki grup arasında parametreler student t test ile değerlendirildi. Bulgular: Çalışmada yer alan hastaların ortalama yaşı 52.9 (%53 erkek) idi. Hastaların %7.6 diyabet, %40.9 hipertansiyon ve %22.7 ‘si sigara kullanıcısı idi. Hesaplanan risk skorları Framingham, PROCAM, SCORE ve TKD (Türk Kardiyoloji Derneği risk skoru) iki grup arasında benzerdi. Bununla beraber anormal egzersiz stres test ile epikardiyal yağ dokusu ve aortik elastik parametreleri (aortik strain ve aortik distensibilite) arasında bir ilişki tespit edilmedi. Anormal egzersiz stres testi olan grupta normal gruba göre trombosit sayısı ve trombosit dağılım genişliği arasında anlamlı farklılık saptandı. ( 298.000 vs 253.000 p:0.035, 16.02 vs 14.8 p: 0.027, sırasıyla). Sonuç: Çalışmamıza göre trombosit sayısı ve trombosit dağılım genişliğinin anormal egzersiz stres testi olanlarda yüksek olması, koroner arter hastalığının ortaya çıkmasında trombositlerin anahtar rol oynadığının göstergesi olabilir.

Keywords

• efor testi
• trombosit dağılım genişliği
• kardiyovasküler risk

References

1. Kones, R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther. 2011; 5(1): 325-80.
2. National Heart, Lung, and Blood Institute. The Framingham Heart Study. Available from: http://www. framingham.com
3. Conroy RM, Pyörälä K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24(11): 987-1003.
4. Safar ME, Blacher J, Jankowski P. Arterial stiffness, pulse pressure, and cardiovascular disease-is it possible to break the vicious circle? Atherosclerosis 2011; 218(3): 263–71.
5. Verhagen SN, Visseren FL. Perivascular adipose tissue: as a cause of atherosclerosis. Atherosclerosis. 2011; 214(1): 3-10.
6. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993; 118(12): 956-63.
7. Grimm RH, Neaton JD, Ludwig W. Prognostic importance of the white cell count for coronary, cancer and all cause mortality. JAMA. 1985; 254(14): 1932-7.
8. Lang RM, Bierig M, Devereux RB et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005; 18(12): 1440-63.

9. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA. Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr. 2002; 15(2): 167-84.
10. Sadi G. Kalp damar hastalıklarında global risk ve hedefler. Türk Kardiyol Dern Arş. 2009; 37( 2): 1-10
11. Gibbons, R, Balady G. Timothybricker et al. "ACC / AHA 2002 guideline update for exercise testing: summary article A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines,Journal of the American College of Cardiology. J Am Coll Cardiol. 2002; 40(8): 1531-40
12. Previtali M, Lanzarini L, Fetiveau R, Poli A, Ferrario M. Comparison of dobutamine stress echocardiography, dipyridamole stress echocardiography and exercise stress testing for diagnosis of coronary artery disease. Am J Cardiol. 1993; 72(12): 865-70.
13. De Wood MA, Spores J, Notske R, et al. Prevalance of total coronary occlusion during the early hours of transmural myocardial infarction. N Eng J Med. 1980; 303(16): 897-902.
14. Davies MJ, Thomas A. Thrombosis and acute coronary- artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984; 310(18): 1137-40.
15. Zack PM, Ischinger T, Aker UT, Dincer B, Kennedy HL. The occurence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J. 1984; 108(6): 1408-12.
16. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005; 45(8): 1157–64.
17. Bath PM, Butterworth RJ. Platelet size measurement, physiology and vascular disease. Blood Coagul Fibrinolysis. 1996; 7(2): 157–61.
18. Halbmayer WM, Haushofer A, Radek J et al. Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease. Coron Artery Dis. 1995; 6(5): 397–402.
19. De Luca G, Venegoni L, Iorio S et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets. 2010; 21(7): 508–14.
20. Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets. 2002; 13(5): 301–06.
21. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J. 2001; 22(17): 1561–71.
22. Brown AS, Hong Y, de Belder A et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17(4): 802–7.
23. Aliberti G, Proietta M, Pulignano I et al. Association between fibrinogen plasma levels and platelet counts in an outpatient population and in patients with coronary heart disease. Blood Coagul Fibrinolysis. 2010; 21(3): 216–20.
24. Würtz M, Hvas AM, Kristensen SD et al. Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res. 2012; 129(1): 56–61.